Eli Lilly & Co. closed 20.65% short of its 52-week high of $972.53, which the company achieved on August 22nd.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating and $1,050 price target on Eli Lilly & Company (NYSE:LLY), pointing to the ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly and Co's stock. This analysis reveals shifts in analysts' expectations over time.

Shares of Eli Lilly (LLY) fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Shares of Eli Lilly are up more than 130% in the past year, but this company's moves are far from finished.

Overall, Eli Lilly posted a solid Q2 and that also reflects in its stock price move. However, we think it’s appropriately valued at levels of over $900.

Eli Lilly's Q3 results show strong sales growth, especially in its Mounjaro and Zepbound franchises, but lowered 2024 outlook leads to investor concerns. Read more here.

Financial Milestones: Eli Lilly's Journey Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers.